Immunology & Inflammation

This technology describes the development of immunogenic compounds to serve as ligands for natural killer T cells to modulate immune responses.

This technology describes human monoclonal antibodies derived from the B cells of a case of zoonotic avian influenza virus H7N9 to treat or prevent H7N9 infections.

This technology is a method to target and eliminate the viral reservoir of latent HIV-1 using latency reversal agents facilitated by targeted delivery with monoclonal antibodies.

This technology identifies the nucleoside triphosphate diphosphohydrolases 8 (NTPDase8) as a therapeutic target for liver ischemia-reperfusion injury.

This technology is a pharmacological intervention targeting localized inflammatory responses in trauma and hemorrhagic shock to prevent multiple organ failure.

This technology is a P2X4 or P2X7 purine receptor-targeted therapy for the treatment of shock-induced multiple organ failure.